Literature DB >> 888449

Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs.

S Higuchi, H Sasaki, Y Shiobara, T Sado.   

Abstract

1. After oral administration of [14C]dihydropyridine diester, the plasma concn. of radioactivity was similar in rats and dogs, reaching a maximum at 0-5 to 1 h and decreasing with a half life of about 3-5 h. The plasma concn. of unmetabolized drug in dogs was 10 times higher than in rats. Radioactivity in rat tissue was high in liver, kidney and lung after both oral and intravenous administration. 2. In both species, 66-72% of radioactivity was excreted in faeces and 23-29% in urine in 48 h, regardless of the route of administration. Biliary excretion in rats after oral dosage amounted to 65%. 3. Eight metabolites were identified from urine of dogs and rats. They were derived from one or several of the following pathways: I, debenzylation of the N-benzyl-N-methylaminoethyl side chain; II, reduction of the 3-nitro group on the phenyl substituent; III, oxidation of the 1,4-dihydropyridine ring to the corresponding pyridine; IV, oxidative removal of the N-benzyl-N-methylamino group yielding a carboxylic acid; V, hydrolysis of the N-benzyl-N-methylamino-ethyl ester to the corresponding carboxylic acid; VI, hydroxylation of the 2-methyl group of the 1,4-dihydropyridine ring to hydroxymethyl.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 888449     DOI: 10.3109/00498257709035806

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

1.  Evaluation of first pass effect and biliary excretion of diperdipine in the dog.

Authors:  P O Greiner; S Weber; J Angignard; B Berbey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

2.  Determination of (+)- and (-)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine.

Authors:  T Iwaoka; N Inotsume; J Inoue; S Naomi; Y Okamoto; S Higuchi; M Nakano; T Umeda
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.

Authors:  J H Ahmed; A C Grant; R S Rodger; G R Murray; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 4.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

5.  Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease.

Authors:  B Silke; D J Graham; S P Verma; G Reynolds; M A Frais; J R Finlayson; S H Taylor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  The metabolism and pharmacokinetics of nicardipine hydrochloride in man.

Authors:  D J Graham; R J Dow; D J Hall; O F Alexander; E J Mroszczak; D Freedman
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Nicardipine in models of myocardial infarction.

Authors:  B J Alps; C Calder; A Wilson
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Influence of digestive secretions and food on intestinal absorption of nicardipine.

Authors:  J C Delchier; M Guerret; N Vidon; C Dubray; D Lavene
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.